SHROOM3

Across TCGA pan-cancer cohorts, SHROOM3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SHROOM3 data layer compared with 23 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SHROOM3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SHROOM3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where SHROOM3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.549	0.204	<.001	34	view →
LUAD	DFS	Tertile	III,IV	0.328	0.825	.019	11	view →
LSCC	DFS	Quartile	II,III,IV	0.856	1.000	.019	8	view →
CCRCC	DFS	Median	All	0.815	0.638	.016	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SHROOM3–PDAC (DFS)

Open the PDAC breakdown →